Datapoint

Datapoint: FDA Approves Biogen’s Lucentis Biosimilar

The FDA on Monday approved Biogen and Samsung Bioepis’ Byooviz, a biosimilar to Roche’s blockbuster eye drug Lucentis. The approval marks Samsung Bioepis’ fifth biosimilar win. For the treatment of age-rel...
0 Comments

Datapoint: Clover Health Offers in-Home Vaccination

In an effort to protect its vulnerable and/or homebound members, Clover Health last week unveiled a partnership with MedArrive and new initiative to vaccinate Medicare Advantage members in their homes. The program...
0 Comments

Datapoint: CMS Extends ACA Enrollment Period

The open enrollment period for Affordable Care Act plans will run from November 1 to January 15, an additional 30 days, according to a release from CMS. This is just one of a series of enhancements, which also inc...
0 Comments

Datapoint: SCAN to Expand to Arizona, Nevada

Medicare Advantage insurer SCAN Health Plan will take on its first-ever expansion outside of California in 2022, bringing its products to Arizona and Nevada. The expansion will bring SCAN’s total reach to 17 m...
0 Comments

Datapoint: Combined Tufts, Harvard Pilgrim Org Select OptumRx as PBM

Point32Health, the organization formed by the merger of Tufts Health Plan and Harvard Pilgrim Health Care, has selected OptumRx as its pharmacy benefit manager, according to a Sept. 9 press release. The three-year ...
0 Comments

Datapoint: Centene to Consolidate Medicare Offerings Under Wellcare Brand

As part of a “brand refresh,” Centene Corp. plans to consolidate its Medicare Advantage offerings under its Wellcare brand, according to a Sept. 1 press release. This includes state-level Centene brands such as...
0 Comments

Datapoint: Court Ruling Shores Up Eliquis Exclusivity Until 2028

The U.S. Court of Appeals for the Federal Circuit on Sept. 3 upheld a lower court decision that maintains Bristol Myers Squibb and Pfizer’s U.S. exclusivity for their blockbuster heart drug Eliquis until 2028. T...
0 Comments

Datapoint: Highmark Completes Purchase of Gateway Health Plan

Highmark Health finalized its purchase of Gateway Health Plan, a Pittsburgh-based Medicaid insurer, according to a Sept. 7 article in the Pittsburgh Post-Gazette. Highmark already owned 50% of the insurer, which...
0 Comments

Datapoint: J&J Scores Approval for First Twice-Yearly Schizophrenia Drug

The FDA last week approved Johnson & Johnson’s Invega Hafyera, a long-acting atypical antipsychotic, for the treatment of schizophrenia, expanding the drugmaker’s hold on the market. The drug is the first-...
0 Comments

Datapoint: Latest Patent Ruling Protects Imbruvica Until 2032

AbbVie and Johnson & Johnson last week won a patent lawsuit in favor of their oncology drug Imbruvica, which now won’t see generic competition until at least 2032. The legal battle against Alvogen and Natco Ph...
0 Comments